US Edition
News from curetoday.com
We’ve assigned a media bias rating of unknown to curetoday.com. You can read more about our methodology here.
Media Bias Ratings
Do you disagree?
Edit bias
Learn more about Media Bias Ratings.
Factuality
Learn more about Factuality Ratings
Reveal Factuality Ratings by upgrading to a Premium account.
Tap Upgrade to explore subscription options to meet all your reading needs.
Ownership
Learn more about Ownership categories
Reveal Ownership Data by upgrading to a Vantage account.
Tap Upgrade to explore subscription options to meet all your reading needs.
Top curetoday.com News
Cancer · United StatesIn a significant stride within the realm of oncology, Bicara Therapeutics Inc. has announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to its investigational therapy, ficerafusp alfa, for the treatment of first-line human papillomavirus (HPV)-negative recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). This designation, which aims to expedite the development and review of the…See the Story
Bicara Therapeutics Ficerafusp Alfa Secures FDA Breakthrough Designation A Promising Horizon for HPV-Negative R/M ...
Health · United States'SAN CARLOS, Calif. '' BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a pioneering global oncology company, has announced a significant milestone in its clinical development programme. The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for sonrotoclax, an advanced and potentially best-in-class investigational BCL2 inhibitor. This designation is aimed at improving treatment options for ad…See the Story
BeOne Medicines Secures FDA Breakthrough Therapy Designation for Sonrotoclax in Treating Mantle Cell Lymphoma,
